PhaseBio Inks License to Develop MedImmune's Reversal Agent for Blood Thinner

PhaseBio Pharmaceuticals said today it has signed an exclusive global license to develop MedImmune’s Phase I–ready reversal agent for parent company AstraZeneca’s marketed blood thinner Brilinta ® (ticagrelor).The exclusive worldwide licensing agreement, whose value was not disclosed, covers PB2452, an intravenous neutralizing Fab antibody fragment intended to reverse the antiplatelet effects of Brilinta (marketed in Europe as Brilique ® ) by binding to it and its activ